Faron Finalizes Agreements for Cancer Immunotherapy Resistance Trial

05:46 AM EST, 12/22/2025 (MT Newswires) -- Faron Pharmaceuticals (FARON.HE, FARN.L) finalized agreements to commence the Blaze trial in the UK, targeting immunotherapy resistance in cancer. The pharmaceutical company will investigate its lead asset, bexmarilimab, in combination with Gilead Sciences' anti-PD-1 checkpoint inhibitor, zimberelimab, for patients with metastatic non-small cell lung cancer and melanoma who have developed resistance to prior anti-PD-1-based immunotherapy and progressed within three months of the last anti-PD-1 treatment, according to a Monday release. Patients will first be primed with bexmarilimab monotherapy, followed by a combination of bexmarilimab and zimberelimab. The investigator-initiated trial is part of a strategic collaboration with The Institute of Cancer Research, London, which is operating in partnership with The Royal Marsden NHS Foundation Trust.